The host tissue microenvironment influences malignant cell proliferation and metastasis, but little is known about how tumor-induced changes in the microenvironment affect benign cellular ecosystems. Applying dynamic in vivo imaging to a mouse model, we show that leukemic cell growth disrupts normal hematopoietic progenitor cell (HPC) bone marrow niches and creates abnormal microenvironments that sequester transplanted human CD34 + (HPC-enriched) cells. CD34 + cells in leukemic mice declined in number over time and failed to mobilize into the peripheral circulation in response to cytokine stimulation. Neutralization of stem cell factor (SCF) secreted by leukemic cells inhibited CD34 + cell migration into malignant niches, normalized CD34 + cell numbers, and restored CD34 + cell mobilization in leukemic mice. These data suggest that the tumor microenvironment causes HPC dysfunction by usurping normal HPC niches and that therapeutic inhibition of HPC interaction with tumor niches may help maintain normal progenitor cell function in the setting of malignancy.
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H ematopoietic progenitor cells (HPCs)
home to and engraft in highly specific bone marrow (BM) microenvironments, or niches, that regulate their survival, proliferation, and differentiation (1, 2) . These niches have been defined by the association of particular stromal cell types and by their elaboration or secretion of specific signaling molecules, growth factors, and cytokines (3) . At least two distinct HPC-supportive niches have been identified in the BM: an osteoblastic niche in which molecules including bone morphogenetic protein, osteopontin, angiopoietin-1, and Notch appear to play important regulatory roles; and a vascular niche that remains to be molecularly defined (4) (5) (6) (7) (8) .
Although defects in hematopoiesis are frequently observed in patients with malignant involvement of the BM, the molecular bases of these phenomena, and whether they might reflect perturbations in HPC-supportive niches, are unknown. Suppression of normal hematopoiesis can occur in the setting of relatively low tumor burden and thus does not necessarily reflect anatomic "crowding out" of benign cells.
Using a severe combined immunodeficiency (SCID) mouse xenograft model of Nalm-6 pre-B acute lymphoblastic leukemia (ALL), we have shown that malignant cells metastasize to specific stromal cell-derived factor-1 (SDF-1)-positive vascular niches in the BM that overlap with perivascular HPC niches (9) . To investigate whether benign and malignant cells compete for niche resources, we used real-time, in vivo confocal and multiphoton microscopy imaging approaches that allowed us to colocalize fluorescently labeled BM antigens with fluorescently labeled human CD34 + cells, which are highly enriched in HPCs, and fluorescent tumor cells (10) . For intravenous transplant into mice, we harvested CD34 + cells from human cord blood and from the peripheral blood of human donors who had been treated SDF-1 is an important chemoattractant for HPC homing to the BM and plays a key role in maintaining hematopoiesis (11) (12) (13) . Because SDF-1 expression is up-regulated in regions of hypoxia or inflammation (14, 15) , we hypothesized that SDF-1 protein levels would be increased in the tumor niche. Surprisingly, however, when we assessed the mice for BM SDF-1 expressioñ 1 month after initial Nalm-6-GFP (green fluorescent protein) engraftment, we found that SDF-1 was markedly down-regulated in regions of heavy tumor growth (Fig. 1B and figs. S3 and S4). These areas of extensive tumor proliferation and SDF-1 down-regulation corresponded to typical CD34 + cell homing niches. Given that leukemic proliferation occurred preferentially within CD34 + cell homing niches and disrupted chemokine SDF-1 expression at these sites, we next examined whether CD34 + cell BM homing was altered in leukemic mice. Nalm-6-GFP leukemic mice versus control mice were engrafted intravenously with purified, fluorescently labeled human CD34 + cells. Whereas in control mice CD34 + cell homing localized to SDF-1-positive parasagittal vascular niches, in leukemic mice CD34 + cell homing was redirected to atypical lateral microenvironments ( Fig.  1C and fig. S5 ). This finding did not reflect an inability of cells to enter parasagittal regions in leukemic mice, because video-rate imaging confirmed that the cells transited freely through parasagittal tumor-associated vasculature [movies S1 and S2 (10) ]. Furthermore, when CD34 + cells were pretreated with pertussis toxin (an inhibitor of chemokine receptor Ga i -mediated signaling) or with AMD3100 (a small-molecule antagonist of the SDF-1 receptor CXCR4), there was no significant decrease in CD34 + cell homing to the BM in tumor mice (figs. S6 and S7). These data suggest that in leukemic mice, CD34
+ cells homed to atypical regions through an SDF-1-and chemokine-independent mechanism. Although CD34 + cells were able to traffic to BM in leukemic mice, our observation that initial homing occurred in abnormal vascular niches raised the possibility that subsequent engraftment would be altered. We therefore performed serial imaging studies of individual mice to assess the intra-BM movement of CD34 + cells. Surprisingly, most CD34 + cells did not remain at sites of initial homing or migrate to other tumor-free niches. Instead, within days, the vast majority of the transplanted cells aberrantly migrated to SDF-1-negative tumor beds, suggesting that the + cell transplantation when compared with control mice (Fig. 2C) . In long-term CD34 + cell-transplanted mice subsequently engrafted with leukemia, CD34 + cell counts also declined significantly (21.7 T 3.3%) over time in leukemic versus control mice (Fig. 2D) . These data suggest that the malignant niche, although outcompeting native niches for CD34 + cell localization, fails to preserve the CD34 + cell pool size seen in normal mice.
HPCs are routinely collected for autologous or allogeneic transplant by harvest from the peripheral blood after these cells are mobilized out of the BM by treatment of patients with the cytokine granulocyte colony-stimulating factor (G-CSF). However, the presence of residual BM disease is associated with decreased CD34 + cell mobilization into the peripheral circulation after cytokine treatment (16) . Addition of the investigational agent AMD3100 to enhance mobilization can also fail to yield adequate stem cell numbers (17) . Although some of this effect may be related to stromal damage from chemoand radiotherapy, a clear cause for mobilization failure has not been established (18) . We therefore examined the effect of malignant niche migration in leukemic mice on CD34 + cell mobilization. CD34 + cells engrafted in leukemic mice minimally mobilized in response to a 5-day course of G-CSF compared with controls (Fig. 2E) . Mobilization was not enhanced by the addition of AMD3100 ( fig. S8 ). We next explored the molecular mechanism responsible for CD34 + cell migration into the malignant niche, with the goal of correcting CD34 + cell dysfunction by inhibiting the transit of these cells from normal microenvironments. To investigate the possibility that the malignant cells might be the source of chemoattractants, we performed transwell migration assays with CD34 + cells and conditioned media (CM) from Nalm-6-GFP, primary human ALL, and primary human acute myeloblastic leukemia (AML) cell cultures. Relative to control media, CD34 + cells migrated in significantly greater numbers (by a factor of 3.5) to leukemia CM (Fig. 3A) . Addition of SDF-1 to CM had an additive, but not synergistic, effect on migration ( fig. S9 ). We next screened CM by Western blot for molecules with chemotactic activity for CD34 + cells. Among our initial candidates was stem cell 
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factor (SCF), an HPC growth factor and chemoattractant believed to play a role in HSC localization to endosteal niches (19) (20) (21) (22) . SCF is produced by a wide variety of solid tumors (23) (24) (25) (26) . AML cell lines and primary AML cells have been shown to produce SCF RNA transcripts, but expression of SCF by hematologic malignancies is not well defined (27) . Figure 3B and fig. S10 show that SCF protein is clearly present in leukemia-CM.
To assess whether SCF expression was upregulated in the leukemic niche in our mouse model, we performed in vivo immunoimaging of control versus Nalm-6-GFP leukemic mice using fluorescently labeled mouse/human crossreactive antibodies to SCF (anti-SCF). Whereas only a faint SCF signal was detectable at baseline in control mouse calvarial BM, SCF was highly expressed in mice imaged~1 month after Nalm-6-GFP engraftment (Fig. 3C) . Immunohistochemical staining of mouse femurs confirmed that human SCF (hSCF) was present at high abundance in this marrow compartment (Fig. 3D ). In addition, Western blotting of control versus leukemic BM showed expression of human SCF protein product ( fig. S11 ). Quantitative reverse transcription-polymerase chain reaction demonstrated a significant decrease in mouse SCF RNA transcript copy numbers, suggesting that leukemic cells constituted the major source of SCF in the malignant microenvironment ( fig. S12 ).
To determine whether CD34 + cell migration into the malignant niche could be prevented by inhibition of SCF activity, we treated Nalm-6-GFP leukemic mice with SCF-neutralizing antibodies beginning 1 day before CD34 + cell engraftment. We found that at 7 days after CD34 + cell engraftment, significantly fewer CD34 + cells had migrated into tumor niches in treated (37%) versus untreated (76%) mice (Fig. 3E) . We also treated long-term CD34 + cell-engrafted mice (12 to 16 weeks) with SCFneutralizing antibodies beginning 1 day before Nalm-6-GFP engraftment and continuing for 30 days. Again, fewer CD34 + cells exited normal niches for the malignant niche compared with the control (Fig. 3F) . To determine if prevention of CD34 + cell egress from benign niches also rescued CD34 + cell function in leukemic mice, we administered a 5-day course of G-CSF (to induce CD34 + cell mobilization) to mice that had been treated with SCF-neutralizing antibody, as well as to control immunoglobulin G (IgG)-treated mice. Sixty-eight percent of CD34 + cells in neutralizing antibodytreated mice mobilized in response to cytokine stimulation versus 14% in untreated mice (Fig. 3G) . In another set of experiments, leukemic mice were treated with SCF-neutralizing antibody versus control IgG beginning 1 day before transplant of CD34 + cells. Mice were killed after 7 days for CD34 + cell harvest and quantitation. More than twice as many CD34 + cells were obtained from treated mice (Fig. 3H) . These data suggest that CD34 + cell pool size could be maintained in leukemic mice by inhibiting CD34 + cell engagement with the malignant niche.
To extend our observations with the Nalm-6 ALL cell line to primary human disease, we performed similar experiments with cells isolated from BM aspirates of ALL or AML patients. Imaging of mice~8 weeks after engraftment of primary pre-B ALL or AML in nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice revealed pronounced up-regulation of SCF signal in the calvarial BM (Fig. 4A and fig. S13 ). CD34 + cells engrafted in these mice exhibited migration into SCF + domains similar to that in Nalm-6-GFP leukemic mice (Fig. 4B) . CD34 + cells also failed to respond to G-CSF mobilization (Fig. 4C) .
Finally, we determined whether changes in SCF expression could be detected in initial diagnostic BM samples from patients with pre-B ALL. Normal BM biopsies (no evidence of disease) and BM biopsies with known ALL involvement were assayed for SCF by immunohistochemistry of paraffinembedded sections. As seen in representative micrographs in Fig. 4D , basal expression was low in all three normal controls, whereas SCF staining was markedly elevated (by a factor of 2; Fig. 4E ) in all seven patient samples.
We have shown that leukemic proliferation in the BM alters the stromal microenvironment and creates malignant niches that outcompete native HPC niches for CD34 + cell engraftment. Normal CD34 + cells engaged by the malignant niche exhibit abnormal behavior. Our data suggest that therapeutic targeting of SCF may increase the hematopoietic reserve and improve outcomes in BM transplantation and autologous stem cell harvest in the setting of hematologic malignancy. The findings from our xenograft model, however, require confirmation in human studies.
Our results raise many questions about the nature of tumor-host interactions: Do leukemic cells reorganize the molecular microenvironment specifically to entrap HPCs, or is the creation of competitive HPC niches a coincidental side effect of leukemic growth? Conceivably, derangements in hematopoiesis and HPC mobilization could impair anti-tumor immune responses. Of note, SCF neutralization did not significantly inhibit Nalm-6 proliferation in our model, and indeed Nalm-6 cells down-regulate their expression of the SCF receptor, KIT, in vivo ( fig. S14 ). These findings, although not definitive, suggest that Nalm-6 SCF production does not principally serve to fuel autocrine tumor growth. Future studies that elucidate the intricacies of these tumor-host interactions are expected to further our understanding of stem and progenitor cell dysfunction in cancer and expose new therapeutic targets. 
Representation of Geometric Borders in the Entorhinal Cortex
Trygve Solstad, Charlotte N. Boccara,* Emilio Kropff,* May-Britt Moser, Edvard I. Moser † We report the existence of an entorhinal cell type that fires when an animal is close to the borders of the proximal environment. The orientation-specific edge-apposing activity of these "border cells" is maintained when the environment is stretched and during testing in enclosures of different size and shape in different rooms. Border cells are relatively sparse, making up less than 10% of the local cell population, but can be found in all layers of the medial entorhinal cortex as well as the adjacent parasubiculum, often intermingled with head-direction cells and grid cells. Border cells may be instrumental in planning trajectories and anchoring grid fields and place fields to a geometric reference frame.
A n animal's current position in the environment is encoded by a network of hippocampal and parahippocampal neurons with diverse spatial firing properties. Within this network, at least three cell types contribute to the computation of self-location: place cells, which fire when the animal moves through a particular location in space (1-3) ; head-direction cells, which fire when the animal is facing in a certain direction (4-7); and grid cells, whose multiple sharply localized firing fields form a remarkably regular triangular pattern across the environment (3, (7) (8) (9) . In addition to these cell types, computational models posit the existence of cortical "boundary vector cells," whose activity patterns encode the animal's distance from salient geometric borders (10, 11) . Based on predictions from these models, we investigated whether proximity to borders is represented by specific cell types in the entorhinal spatial representation circuit (12) .
A total of 624 principal cells were recorded from the dorsocaudal quarter of the medial entorhinal cortex (MEC) and adjacent parasubiculum in 13 rats ( fig. S1 ). Neural activity was sampled while these animals foraged in enclosures with moveable walls and barriers. The animals were first tested in a square enclosure (1 m by 1 m or 1.5 m by 1.5 m) with 50-cmhigh walls. Many recorded cells were grid cells and head-direction cells (7) (8) (9) , but in addition the data included a previously unknown class of entorhinal cells that fired exclusively along one or several walls of the enclosure (Fig. 1 and  fig. S2 ). These cells were identified by computing, for each cell, the difference between the maximal length of a wall touching upon a single firing field and the average distance of the fields from the nearest wall, divided by the sum of those values (12) . Border scores ranged from -1 for cells with central firing fields to +1 for cells with fields that perfectly lined up along at least one entire wall. "Border cells" were defined as spatially stable cells with border scores above 0.5. A total of 69 cells from 12 animals passed this criterion ( Fig. 1 and  fig. S2 ) (13) . In these cells, 86.0 T 0.6% of the spikes occurred closer to the walls than to the center of the box per unit of time [mean T SEM; t(68) = 17.4, one-sample t test, P < 0.001; expected value 75%]. Only 3.6 T 1.0% of the Kavli Institute for Systems Neuroscience and Centre for the Biology of Memory, Norwegian University of Science and Technology, 7489 Trondheim, Norway.
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